ID   RT-112
AC   CVCL_1670
SY   RT 112; RT112
DR   BTO; BTO:0003724
DR   CLO; CLO_0008890
DR   EFO; EFO_0006479
DR   ArrayExpress; E-MTAB-2706
DR   ArrayExpress; E-MTAB-2770
DR   ArrayExpress; E-MTAB-3610
DR   BioSample; SAMN03473091
DR   BioSample; SAMN03473589
DR   BioSample; SAMN10988358
DR   CCLE; RT112_URINARY_TRACT
DR   Cell_Model_Passport; SIDM00402
DR   ChEMBL-Cells; CHEMBL3307307
DR   ChEMBL-Targets; CHEMBL614145
DR   CLS; 300324/p10280_RT-112
DR   Cosmic; 715739
DR   Cosmic; 760482
DR   Cosmic; 845559
DR   Cosmic; 867837
DR   Cosmic; 909704
DR   Cosmic; 925820
DR   Cosmic; 928823
DR   Cosmic; 1046682
DR   Cosmic; 1068092
DR   Cosmic; 1285124
DR   Cosmic; 1285984
DR   Cosmic; 1819324
DR   Cosmic; 1938478
DR   Cosmic; 1938697
DR   Cosmic; 2037954
DR   Cosmic; 2050459
DR   Cosmic; 2057454
DR   Cosmic; 2444244
DR   Cosmic; 2686111
DR   Cosmic-CLP; 909704
DR   DepMap; ACH-000473
DR   DSMZ; ACC-418
DR   GDSC; 909704
DR   GEO; GSM887552
DR   GEO; GSM888635
DR   GEO; GSM1374857
DR   GEO; GSM1374858
DR   GEO; GSM1574545
DR   GEO; GSM1574581
DR   GEO; GSM1670393
DR   IARC_TP53; 13322
DR   LiGeA; CCLE_846
DR   LINCS_LDP; LCL-1716
DR   PharmacoDB; RT112_1332_2019
DR   Wikidata; Q54951347
RX   PubMed=571047;
RX   PubMed=864752;
RX   PubMed=870558;
RX   PubMed=2903891;
RX   PubMed=3708594;
RX   PubMed=6823318;
RX   PubMed=7490993;
RX   PubMed=8873383;
RX   PubMed=11207054;
RX   PubMed=11921286;
RX   PubMed=12127398;
RX   PubMed=15846775;
RX   PubMed=20164919;
RX   PubMed=22460905;
RX   PubMed=24018021;
RX   PubMed=24035680;
RX   PubMed=24367658;
RX   PubMed=25485619;
RX   PubMed=25984343;
RX   PubMed=25997541;
RX   PubMed=26055179;
RX   PubMed=27270441;
RX   PubMed=27397505;
RX   PubMed=28855393;
RX   PubMed=29732388;
RX   PubMed=30894373;
RX   PubMed=31068700;
WW   http://faculty.washington.edu/trawets/archive/Human/bladder/rt112/index.html
WW   https://www.synapse.org/UC25
CC   Part of: Cancer Cell Line Encyclopedia (CCLE) project.
CC   Part of: COSMIC cell lines project.
CC   Part of: UBC-40 urothelial bladder cancer cell line index.
CC   Doubling time: 24 hours (PubMed=3708594); 25 hours (PubMed=25984343); 25.7 hours (PubMed=26055179); ~35 hours (DSMZ).
CC   Microsatellite instability: Stable (MSS) (Sanger).
CC   Sequence variation: FGFR3-TACC3 gene fusion (PubMed=25485619; PubMed=28855393).
CC   Sequence variation: TERT c.228C>T (-124C>T); in promoter (PubMed=24035680; PubMed=31068700).
CC   Sequence variation: Heterozygous for TP53 p.Ser183Ter (c.548C>G) and p.Arg248Gln (c.743G>A) (CCLE; Cosmic-CLP).
CC   Omics: CNV analysis.
CC   Omics: Deep exome analysis.
CC   Omics: Deep RNAseq analysis.
CC   Omics: DNA methylation analysis.
CC   Omics: shRNA library screening.
CC   Omics: SNP array analysis.
CC   Omics: Transcriptome analysis.
CC   Genome ancestry: African=0%; Native American=0%; East Asian, North=1.6%; East Asian, South=0%; South Asian=0%; European, North=65.6%; European, South=32.8% (PubMed=30894373).
ST   Source(s): CLS; Cosmic-CLP; DSMZ; PubMed=11416159; PubMed=25877200; PubMed=27270441
ST   Amelogenin: X
ST   CSF1PO: 10,11 (CLS; Cosmic-CLP; DSMZ; PubMed=27270441)
ST   CSF1PO: 10 (PubMed=25877200)
ST   D13S317: 13,14
ST   D16S539: 11,13
ST   D18S51: 15 (CLS)
ST   D18S51: 15,17 (PubMed=25877200)
ST   D21S11: 27,30
ST   D3S1358: 15
ST   D5S818: 10,13
ST   D7S820: 11,12
ST   D8S1179: 13,15
ST   FGA: 23 (CLS)
ST   FGA: 23,25 (PubMed=25877200)
ST   Penta D: 10,11 (CLS)
ST   Penta D: 10 (PubMed=25877200)
ST   Penta E: 12,16
ST   TH01: 7
ST   TPOX: 8,11
ST   vWA: 14,17
DI   NCIt; C4912; Bladder carcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens
SX   Female
AG   Age unspecified
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 06-09-19; Version: 28
//
RX   PubMed=571047;
RA   Fogh J.;
RT   "Cultivation, characterization, and identification of human tumor
RT   cells with emphasis on kidney, testis, and bladder tumors.";
RL   Natl. Cancer Inst. Monogr. 49:5-9(1978).
//
RX   PubMed=864752; DOI=10.1093/jnci/58.6.1743;
RA   Marshall C.J., Franks L.M., Carbonell A.W.;
RT   "Markers of neoplastic transformation in epithelial cell lines derived
RT   from human carcinomas.";
RL   J. Natl. Cancer Inst. 58:1743-1751(1977).
//
RX   PubMed=870558; DOI=10.1177/25.4.870558;
RA   Benham F.J., Cottell D.C., Franks L.M., Wilson P.D.;
RT   "Alkaline phosphatase activity in human bladder tumor cell lines.";
RL   J. Histochem. Cytochem. 25:266-274(1977).
//
RX   PubMed=2903891; DOI=10.1080/09553008814552341;
RA   Peacock J.H., Cassoni A.M., McMillan T.J., Steel G.G.;
RT   "Radiosensitive human tumour cell lines may not be recovery
RT   deficient.";
RL   Int. J. Radiat. Biol. 54:945-953(1988).
//
RX   PubMed=3708594;
RA   Masters J.R.W., Hepburn P.J., Walker L., Highman W.J.,
RA   Trejdosiewicz L.K., Povey S., Parkar M., Hill B.T., Riddle P.R.,
RA   Franks L.M.;
RT   "Tissue culture model of transitional cell carcinoma: characterization
RT   of twenty-two human urothelial cell lines.";
RL   Cancer Res. 46:3630-3636(1986).
//
RX   PubMed=6823318; DOI=10.1038/301429a0;
RA   O'Toole C.M., Povey S., Hepburn P.J., Franks L.M.;
RT   "Identity of some human bladder cancer cell lines.";
RL   Nature 301:429-430(1983).
//
RX   PubMed=7490993; DOI=10.1016/S0140-6736(95)92474-4;
RA   Gaetje R., Kotzian S., Herrmann G., Baumann R., Starzinski-Powitz A.;
RT   "Invasiveness of endometriotic cells in vitro.";
RL   Lancet 346:1463-1464(1995).
//
RX   PubMed=8873383; DOI=10.1007/BF00295899;
RA   Stadler W.M., Olopade O.I.;
RT   "The 9p21 region in bladder cancer cell lines: large homozygous
RT   deletion inactivate the CDKN2, CDKN2B and MTAP genes.";
RL   Urol. Res. 24:239-244(1996).
//
RX   PubMed=11207054; DOI=10.1054/bjoc.2000.1641;
RA   Fujiyama C., Jones A., Fuggle S., Bicknell R., Cranston D.,
RA   Harris A.L.;
RT   "Human bladder cancer invasion model using rat bladder in vitro and
RT   its use to test mechanisms and therapeutic inhibitors of invasion.";
RL   Br. J. Cancer 84:558-564(2001).
//
RX   PubMed=11921286; DOI=10.1002/gcc.10050;
RA   Williams S.V., Sibley K.D., Davies A.M., Nishiyama H., Hornigold N.,
RA   Coulter J., Kennedy W.J., Skilleter A., Habuchi T., Knowles M.A.;
RT   "Molecular genetic analysis of chromosome 9 candidate tumor-suppressor
RT   loci in bladder cancer cell lines.";
RL   Genes Chromosomes Cancer 34:86-96(2002).
//
RX   PubMed=12127398; DOI=10.1016/S0165-4608(01)00648-3;
RA   Strefford J.C., Lillington D.M., Steggall M., Lane T.M., Nouri A.M.E.,
RA   Young B.D., Oliver R.T.D.;
RT   "Novel chromosome findings in bladder cancer cell lines detected with
RT   multiplex fluorescence in situ hybridization.";
RL   Cancer Genet. Cytogenet. 135:139-146(2002).
//
RX   PubMed=15846775; DOI=10.1002/gcc.20166;
RA   Williams S.V., Adams J., Coulter J., Summersgill B.M., Shipley J.M.,
RA   Knowles M.A.;
RT   "Assessment by M-FISH of karyotypic complexity and cytogenetic
RT   evolution in bladder cancer in vitro.";
RL   Genes Chromosomes Cancer 43:315-328(2005).
//
RX   PubMed=20164919; DOI=10.1038/nature08768;
RA   Bignell G.R., Greenman C.D., Davies H., Butler A.P., Edkins S.,
RA   Andrews J.M., Buck G., Chen L., Beare D., Latimer C., Widaa S.,
RA   Hinton J., Fahey C., Fu B., Swamy S., Dalgliesh G.L., Teh B.T.,
RA   Deloukas P., Yang F., Campbell P.J., Futreal P.A., Stratton M.R.;
RT   "Signatures of mutation and selection in the cancer genome.";
RL   Nature 463:893-898(2010).
//
RX   PubMed=22460905; DOI=10.1038/nature11003;
RA   Barretina J.G., Caponigro G., Stransky N., Venkatesan K., Margolin A.A.,
RA   Kim S., Wilson C.J., Lehar J., Kryukov G.V., Sonkin D., Reddy A.,
RA   Liu M., Murray L., Berger M.F., Monahan J.E., Morais P., Meltzer J.,
RA   Korejwa A., Jane-Valbuena J., Mapa F.A., Thibault J., Bric-Furlong E.,
RA   Raman P., Shipway A., Engels I.H., Cheng J., Yu G.K., Yu J.,
RA   Aspesi P. Jr., de Silva M., Jagtap K., Jones M.D., Wang L., Hatton C.,
RA   Palescandolo E., Gupta S., Mahan S., Sougnez C., Onofrio R.C.,
RA   Liefeld T., MacConaill L.E., Winckler W., Reich M., Li N., Mesirov J.P.,
RA   Gabriel S.B., Getz G., Ardlie K., Chan V., Myer V.E., Weber B.L.,
RA   Porter J., Warmuth M., Finan P., Harris J.L., Meyerson M., Golub T.R.,
RA   Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.;
RT   "The Cancer Cell Line Encyclopedia enables predictive modelling of
RT   anticancer drug sensitivity.";
RL   Nature 483:603-607(2012).
//
RX   PubMed=24018021; DOI=10.1016/j.eururo.2013.08.052;
RA   Allory Y., Beukers W., Sagrera A., Flandez M., Marques M., Marquez M.,
RA   van der Keur K.A., Dyrskjot L., Lurkin I., Vermeij M., Carrato A.,
RA   Lloreta J., Lorente J.A., Carrillo-de-Santa-Pau E., Masius R.G.,
RA   Kogevinas M., Steyerberg E.W., van Tilborg A.A.G., Abas C.,
RA   Orntoft T.F., Zuiverloon T.C.M., Malats N., Zwarthoff E.C., Real F.X.;
RT   "Telomerase reverse transcriptase promoter mutations in bladder
RT   cancer: high frequency across stages, detection in urine, and lack of
RT   association with outcome.";
RL   Eur. Urol. 65:360-366(2014).
//
RX   PubMed=24035680; DOI=10.1016/j.eururo.2013.08.057;
RA   Hurst C.D., Platt F.M., Knowles M.A.;
RT   "Comprehensive mutation analysis of the TERT promoter in bladder
RT   cancer and detection of mutations in voided urine.";
RL   Eur. Urol. 65:367-369(2014).
//
RX   PubMed=24367658; DOI=10.1371/journal.pone.0084411;
RA   Ross R.L., Burns J.E., Taylor C.F., Mellor P., Anderson D.H.,
RA   Knowles M.A.;
RT   "Identification of mutations in distinct regions of p85 alpha in
RT   urothelial cancer.";
RL   PLoS ONE 8:E84411-E84411(2013).
//
RX   PubMed=25485619; DOI=10.1038/nbt.3080;
RA   Klijn C., Durinck S., Stawiski E.W., Haverty P.M., Jiang Z., Liu H.,
RA   Degenhardt J., Mayba O., Gnad F., Liu J., Pau G., Reeder J., Cao Y.,
RA   Mukhyala K., Selvaraj S.K., Yu M., Zynda G.J., Brauer M.J., Wu T.D.,
RA   Gentleman R.C., Manning G., Yauch R.L., Bourgon R., Stokoe D.,
RA   Modrusan Z., Neve R.M., de Sauvage F.J., Settleman J., Seshagiri S.,
RA   Zhang Z.;
RT   "A comprehensive transcriptional portrait of human cancer cell
RT   lines.";
RL   Nat. Biotechnol. 33:306-312(2015).
//
RX   PubMed=25984343; DOI=10.1038/sdata.2014.35;
RA   Cowley G.S., Weir B.A., Vazquez F., Tamayo P., Scott J.A., Rusin S.,
RA   East-Seletsky A., Ali L.D., Gerath W.F.J., Pantel S.E., Lizotte P.H.,
RA   Jiang G., Hsiao J., Tsherniak A., Dwinell E., Aoyama S., Okamoto M.,
RA   Harrington W., Gelfand E., Green T.M., Tomko M.J., Gopal S.,
RA   Wong T.C., Li H., Howell S., Stransky N., Liefeld T., Jang D.,
RA   Bistline J., Hill Meyers B., Armstrong S.A., Anderson K.C.,
RA   Stegmaier K., Reich M., Pellman D., Boehm J.S., Mesirov J.P.,
RA   Golub T.R., Root D.E., Hahn W.C.;
RT   "Parallel genome-scale loss of function screens in 216 cancer cell
RT   lines for the identification of context-specific genetic
RT   dependencies.";
RL   Sci. Data 1:140035-140035(2014).
//
RX   PubMed=25997541; DOI=10.1186/s12864-015-1450-3;
RA   Earl J., Rico D., Carrillo-de-Santa-Pau E., Rodriguez-Santiago B.,
RA   Mendez-Pertuz M., Auer H., Gomez G., Grossman H.B., Pisano D.G.,
RA   Schulz W.A., Perez-Jurado L.A., Carrato A., Theodorescu D.,
RA   Chanock S.J., Valencia A., Real F.X.;
RT   "The UBC-40 Urothelial Bladder Cancer cell line index: a genomic
RT   resource for functional studies.";
RL   BMC Genomics 16:403-403(2015).
//
RX   PubMed=26055179; DOI=10.1016/j.tranon.2015.04.002;
RA   Vallo S., Michaelis M., Rothweiler F., Bartsch G., Gust K.M.,
RA   Limbart D.M., Rodel F., Wezel F., Haferkamp A., Cinatl J. Jr.;
RT   "Drug-resistant urothelial cancer cell lines display diverse
RT   sensitivity profiles to potential second-line therapeutics.";
RL   Transl. Oncol. 8:210-216(2015).
//
RX   PubMed=27270441; DOI=10.1038/onc.2016.172;
RA   Nickerson M.L., Witte N., Im K.M., Turan S., Owens C., Misner K.,
RA   Tsang S.X., Cai Z., Wu S., Dean M., Costello J.C., Theodorescu D.;
RT   "Molecular analysis of urothelial cancer cell lines for modeling tumor
RT   biology and drug response.";
RL   Oncogene 36:35-46(2017).
//
RX   PubMed=27397505; DOI=10.1016/j.cell.2016.06.017;
RA   Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P.,
RA   Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H.,
RA   Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H.,
RA   Deng X., Egan R.K., Liu Q., Mironenko T., Mitropoulos X.,
RA   Richardson L., Wang J., Zhang T., Moran S., Sayols S., Soleimani M.,
RA   Tamborero D., Lopez-Bigas N., Ross-Macdonald P., Esteller M.,
RA   Gray N.S., Haber D.A., Stratton M.R., Benes C.H., Wessels L.F.A.,
RA   Saez-Rodriguez J., McDermott U., Garnett M.J.;
RT   "A landscape of pharmacogenomic interactions in cancer.";
RL   Cell 166:740-754(2016).
//
RX   PubMed=28855393; DOI=10.1098/rsob.170080;
RA   Sarkar S., Ryan E.L., Royle S.J.;
RT   "FGFR3-TACC3 cancer gene fusions cause mitotic defects by removal of
RT   endogenous TACC3 from the mitotic spindle.";
RL   Open Biol. 7:170080.1-170080.11(2017).
//
RX   PubMed=29732388; DOI=10.3233/BLC-180167;
RA   Zuiverloon T.C.M., de Jong F.C., Costello J.C., Theodorescu D.;
RT   "Systematic review: characteristics and preclinical uses of bladder
RT   cancer cell lines.";
RL   Bladder Cancer 4:169-183(2018).
//
RX   PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747;
RA   Dutil J., Chen Z., Monteiro A.N., Teer J.K., Eschrich S.A.;
RT   "An interactive resource to probe genetic diversity and estimated
RT   ancestry in cancer cell lines.";
RL   Cancer Res. 79:1263-1273(2019).
//
RX   PubMed=31068700; DOI=10.1038/s41586-019-1186-3;
RA   Ghandi M., Huang F.W., Jane-Valbuena J., Kryukov G.V., Lo C.C.,
RA   McDonald E.R. III, Barretina J., Gelfand E.T., Bielski C.M., Li H.,
RA   Hu K., Andreev-Drakhlin A.Y., Kim J., Hess J.M., Haas B.J., Aguet F.,
RA   Weir B.A., Rothberg M.V., Paolella B.R., Lawrence M.S., Akbani R.,
RA   Lu Y., Tiv H.L., Gokhale P.C., de Weck A., Mansour A.A., Oh C.,
RA   Shih J., Hadi K., Rosen Y., Bistline J., Venkatesan K., Reddy A.,
RA   Sonkin D., Liu M., Lehar J., Korn J.M., Porter D.A., Jones M.D.,
RA   Golji J., Caponigro G., Taylor J.E., Dunning C.M., Creech A.L.,
RA   Warren A.C., McFarland J.M., Zamanighomi M., Kauffmann A.,
RA   Stransky N., Imielinski M., Maruvka Y.E., Cherniack A.D.,
RA   Tsherniak A., Vazquez F., Jaffe J.D., Lane A.A., Weinstock D.M.,
RA   Johannessen C.M., Morrissey M.P., Stegmeier F., Schlegel R.,
RA   Hahn W.C., Getz G., Mills G.B., Boehm J.S., Golub T.R., Garraway L.A.,
RA   Sellers W.R.;
RT   "Next-generation characterization of the Cancer Cell Line
RT   Encyclopedia.";
RL   Nature 569:503-508(2019).
//